349 related articles for article (PubMed ID: 25246276)
1. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
2. Activation of integrin-ERBB2 signaling in undifferentiated thyroid cancer.
Zhu X; Zhu YJ; Kim DW; Meltzer P; Cheng SY
Am J Cancer Res; 2014; 4(6):776-88. PubMed ID: 25520867
[TBL] [Abstract][Full Text] [Related]
3. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
[TBL] [Abstract][Full Text] [Related]
4. Activation of tumor cell proliferation by thyroid hormone in a mouse model of follicular thyroid carcinoma.
Lu C; Zhu X; Willingham MC; Cheng SY
Oncogene; 2012 Apr; 31(16):2007-16. PubMed ID: 21909131
[TBL] [Abstract][Full Text] [Related]
5. Role of TSH in the spontaneous development of asymmetrical thyroid carcinoma in mice with a targeted mutation in a single allele of the thyroid hormone-β receptor.
Zhao L; Zhu X; Won Park J; Fozzatti L; Willingham M; Cheng SY
Endocrinology; 2012 Oct; 153(10):5090-100. PubMed ID: 22919057
[TBL] [Abstract][Full Text] [Related]
6. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
7. Diet-induced obesity increases tumor growth and promotes anaplastic change in thyroid cancer in a mouse model.
Kim WG; Park JW; Willingham MC; Cheng SY
Endocrinology; 2013 Aug; 154(8):2936-47. PubMed ID: 23748362
[TBL] [Abstract][Full Text] [Related]
8. Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer.
Fozzatti L; Park JW; Zhao L; Willingham MC; Cheng SY
PLoS One; 2013; 8(6):e67954. PubMed ID: 23840792
[TBL] [Abstract][Full Text] [Related]
9. Mutation of thyroid hormone receptor-β in mice predisposes to the development of mammary tumors.
Guigon CJ; Kim DW; Willingham MC; Cheng SY
Oncogene; 2011 Jul; 30(30):3381-90. PubMed ID: 21399657
[TBL] [Abstract][Full Text] [Related]
10. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.
Ying H; Suzuki H; Furumoto H; Walker R; Meltzer P; Willingham MC; Cheng SY
Carcinogenesis; 2003 Sep; 24(9):1467-79. PubMed ID: 12869418
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer.
Furuya F; Lu C; Willingham MC; Cheng SY
Carcinogenesis; 2007 Dec; 28(12):2451-8. PubMed ID: 17660507
[TBL] [Abstract][Full Text] [Related]
12. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
13. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
[TBL] [Abstract][Full Text] [Related]
14. SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model.
Zhu X; Kim DW; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jul; 23(7):521-33. PubMed ID: 27267120
[TBL] [Abstract][Full Text] [Related]
15. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Guigon CJ; Cheng SY
Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
[TBL] [Abstract][Full Text] [Related]
16. Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis.
Lu C; Cheng SY
Steroids; 2011 Aug; 76(9):885-91. PubMed ID: 21473875
[TBL] [Abstract][Full Text] [Related]
17. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas.
Borbone E; Troncone G; Ferraro A; Jasencakova Z; Stojic L; Esposito F; Hornig N; Fusco A; Orlando V
J Clin Endocrinol Metab; 2011 Apr; 96(4):1029-38. PubMed ID: 21289264
[TBL] [Abstract][Full Text] [Related]
18. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
19. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of STAT3 activity delays obesity-induced thyroid carcinogenesis in a mouse model.
Park JW; Han CR; Zhao L; Willingham MC; Cheng SY
Endocr Relat Cancer; 2016 Jan; 23(1):53-63. PubMed ID: 26552408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
